Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases

International Journal of Molecular Sciences

Meyoung-Kon Kim¹  SerkIn Park¹  YoungMi Whang²  InHo Chang²  SeungPil Jung³ 

[1] Department of Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul 02841, Korea;Department of Urology, Chung-Ang University College of Medicine, Seoul 06973, Korea;Division of Breast and Endocrine Surgery, Department of Surgery, Korea University Anam Hospital, Seoul 02841, Korea;

关键词: bone;    metastasis;    microenvironment;    osteoblasts;    osteoclasts;    bone marrow;    c-Met and hepatocyte growth factor;   

DOI  :  10.3390/ijms20020384

来源: DOAJ

【 摘 要 】

Bone metastasis is the terminal stage disease of prostate, breast, renal, and lung cancers, and currently no therapeutic approach effectively cures or prevents its progression to bone metastasis. One of the hurdles to the development of new drugs for bone metastasis is the complexity and heterogeneity of the cellular components in the metastatic bone microenvironment. For example, bone cells, including osteoblasts, osteoclasts, and osteocytes, and the bone marrow cells of diverse hematopoietic lineages interact with each other via numerous cytokines and receptors. c-Met tyrosine kinase receptor and its sole ligand hepatocyte growth factor (HGF) are enriched in the bone microenvironment, and their expression correlates with the progression of bone metastasis. However, no drugs or antibodies targeting the c-Met/HGF signaling axis are currently available in bone metastatic patients. This significant discrepancy should be overcome by further investigation of the roles and regulation of c-Met and HGF in the metastatic bone microenvironment. This review paper summarizes the key findings of c-Met and HGF in the development of novel therapeutic approaches for bone metastasis.

【 授权许可】

Unknown